Pancreatitis is rare and, in trial data, has not occurred at rates higher than placebo
Here are some key aspects of our SIBO treatment approach that we employ in our naturopathic clinic in San Diego, California: 1
Studies show that semaglutide use causes chronic conditions in 10% of patients , while around 1% of patients develop more serious conditions like gastroparesis or bowel obstruction
Ashwood et al
To investigate the relative contribution of non-genetic factors that predict GLP1 medication efficacy, we fit a linear model to assess the combined effect of age, sex, pre-treatment BMI, drug type, drug dose and time on drug on total BMI loss (Supplementary Table 3)
GLP-1 is an incretin hormone that is released from the distal ileum in the small intestine and the colon within minutes of ingesting food